WorldPharmaNews
Search ...
Home
Business
Research
Events
Regulatory
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.
www.gsk.com
List of articles in category GlaxoSmithKline
Title
Published Date
GSK rejects conclusions of Senate Committee on Finance Staff Report on Avandia
22 February 2010
GSK rejects conclusions reported in The New York Times story on Avandia
21 February 2010
GlaxoSmithKline and XenoPort receive FDA Complete Response letter for Horizantâ¢
19 February 2010
GSK launches new specialist unit to research and develop medicines for rare diseases
08 February 2010
GSK publishes speaking, consulting fees paid to US healthcare professionals
17 December 2009
GSK and Intercell form strategic alliance to develop and commercialise innovative vaccines
14 December 2009
GSK's Arepanrix⢠H1N1 pandemic vaccine prequalified by the World Health Organization
03 December 2009
GSK and Nabi announce agreement for NicVAX®, a vaccine for nicotine addiction
19 November 2009
FDA approves GSK's pandemic H1N1 vaccine
12 November 2009
WHO Grants Prequalification for Global Use to GSK's 10-Valent Synflorix⢠Vaccine
09 November 2009
Start
Prev
12
13
14
15
16
17
18
19
20
21
Next
End
Business & Industry
Pfizer reports record full-year 2022 results
AMJEVITA™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries
Research & Development
Scientists pinpoint protein that helps cancer-causing viruses evade immune response
Transforming the way cancer vaccines are designed and made
Antidepressants used for chronic pain on the rise, but are they effective?
Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment
Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
Power of cancer drugs may see boost by targeting newly ID'd pathway
Conferences & Events
SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
SAE Media Group's 6th annual 3D Cell Culture Conference
CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
CPHI Excellence in Pharma Award Winners 2022
CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
FDA grants Accelerated Approval for Alzheimer's disease treatment
FDA approves new HIV drug for adults with limited treatment options
FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
FDA approves first gene therapy to treat adults with Hemophilia B
FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
You are here:
Home
GlaxoSmithKline
GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis